Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress - The ...

Detailed price information for Cabaletta Bio Inc (CABA-Q) from The Globe and Mail including charting and trades.
JD Supra

2026 mid-year PFAS update: How federal and state regulation is shaping compliance and litigation risk

Federal and state regulation of per- and polyfluoroalkyl substances (PFAS), as well as related policy initiatives such as Make America Healthy ...

Zealand Pharma A/S: Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat ...

Company announcement No. 21 / 2026 Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss ...